Increased evidence that prostate-cancer-specific mortality can be reduced using serum PSA screening, in addition to the increasing role of active surveillance in reducing overtreatment underlies the revised USPSTF recommendation, which now supports selective use of PSA testing. However, this recommendation should not be interpreted as a license to return to the unthinking use of PSA testing of men between 50 to 70 years of age.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bibbins-Domingo, K., Grossman, D. C. & Curry, S. J. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA 317, 1949–1950 (2017).
Carlsson, S. et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J. Clin. Oncol. 30, 2581–2584 (2012).
Drazer, M. W. et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 15, 1491–1498 (2014).
Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26–37 (2017).
Eapen, R. S., Herlemann, A., Washington, S. L. III & Cooperberg, M. R. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Curr. Opin. Urol. 27, 205–209 (2017).
Moyer, V. A. & U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 10–134 (2012).
Schröder, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014).
Buzzoni, C. et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. 68, 885–890 (2015).
Murphy, D. G. & Loeb, S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat. Rev. Urol. 12, 604–605 (2015).
Bokhorst, L. P. et al. A decade of active surveillance in the PRIAS Study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur. Urol. 70, 954–960 (2016).
The authors declare no competing financial interests.
About this article
Cite this article
Van der Kwast, T., Roobol, M. Draft USPSTF 2017 recommendation on PSA testing — a sea-change?. Nat Rev Urol 14, 457–458 (2017). https://doi.org/10.1038/nrurol.2017.89
Analysis of serum glycome by lectin microarrays for prostate cancer patients - a search for aberrant glycoforms
Glycoconjugate Journal (2020)
Expert Review of Molecular Diagnostics (2019)
Interface Focus (2019)
Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core
Biosensors and Bioelectronics (2019)
Radiologic Clinics of North America (2018)